GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mustang Bio Inc (NAS:MBIO) » Definitions » EPS without NRI

Mustang Bio (Mustang Bio) EPS without NRI : $-5.90 (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Mustang Bio EPS without NRI?

Mustang Bio's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.44. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.90.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 30.10% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 19.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Mustang Bio's EPS without NRI or its related term are showing as below:

MBIO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.4   Med: 12.6   Max: 30.1
Current: 30.1

During the past 9 years, Mustang Bio's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 30.10% per year. The lowest was -39.40% per year. And the median was 12.60% per year.

MBIO's 3-Year EPS without NRI Growth Rate is ranked better than
78.49% of 1297 companies
in the Biotechnology industry
Industry Median: 4.9 vs MBIO: 30.10

Mustang Bio's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.71. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.00.

Mustang Bio's EPS (Basic) for the three months ended in Dec. 2023 was $-0.71. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.00.


Mustang Bio EPS without NRI Historical Data

The historical data trend for Mustang Bio's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mustang Bio EPS without NRI Chart

Mustang Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only -19.35 -17.10 -11.40 -10.09 -5.85

Mustang Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.48 -2.06 -2.00 -1.40 -0.44

Competitive Comparison of Mustang Bio's EPS without NRI

For the Biotechnology subindustry, Mustang Bio's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mustang Bio's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mustang Bio's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Mustang Bio's PE Ratio without NRI falls into.



Mustang Bio EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mustang Bio  (NAS:MBIO) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Mustang Bio EPS without NRI Related Terms

Thank you for viewing the detailed overview of Mustang Bio's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Mustang Bio (Mustang Bio) Business Description

Traded in Other Exchanges
N/A
Address
377 Plantation Street, Worcester, MA, USA, 01605
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors.
Executives
Fortress Biotech, Inc. 10 percent owner 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Manuel Md Litchman director, officer: President and CEO 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10017
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Brian Achenbach officer: SVP, Fin. & Corp. Controller 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Adam J. Chill director 24 NEW ENGLAND EXECUTIVE PARK, SUITE 105, BURLINGTON MA 01803
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Michael J Zelefsky director
David J Horin officer: Interim CFO 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020

Mustang Bio (Mustang Bio) Headlines

From GuruFocus